Medical Tapes And Bandages Market to Witness Exponential Growth by 2028: Grand View Research Inc.

 Medical Tapes And Bandages Market Growth & Trends

The global medical tapes and bandages market size is expected to reach USD 14.44 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.5% from 2021 to 2028. The increasing number of accidents, the impact of COVID-19, and technological advancements are the key factors driving the market. 

Ambulatory surgery centers (ASCs) offer a variety of services, such as surgical care, diagnostics, and preventive procedures. Surgeries for pain management, urology, orthopedics, restorative, reconstructive, or alterative plastic surgeries and gastrointestinal (GI)-related surgeries are also performed in ambulatory surgery centers. Earlier, ASCs were only capable of performing GI-related minor surgeries, however, with an increase in the number of minimally invasive surgical procedures, services offered by ambulatory surgical centers expanded and grew exponentially. According to the U.S. Department of Health and Human Services (HHS) data records of 2016, there were 17.2 million hospital visits. These included invasive, therapeutic surgeries, and ambulatory surgeries. Around 9.94 million (57.8%) of these surgeries occurred in hospital-owned ambulatory surgery settings and the remaining 7.26 million surgeries (42.2%) were conducted in hospitals.

ASCs are increasing in number and they offer cost-effective services. In addition, favorable reimbursement coverages are being provided with regard to services provided by ASCs. The chances of contracting post-surgical, hospital-related infections are also reduced. ASCs provide specific instructions to patients regarding dressing and post-surgical homecare. Thus, with an increase in the number of ASCs and the number of surgeries being performed, demand for medical tapes and bandages is expected to increase.

Request a free sample copy or view report summary: Medical Tapes And Bandages Market Report

Medical Tapes And Bandages Market Report Highlights

• Based on product, the medical bandages segment held the largest share in 2020. The rising number of road accidents across the globe is the major factor propelling the segment growth
• On the basis of application, the surgical wound segment held the largest market share in 2020 and is expected to witness considerable growth over the forecast period due to the increasing number of surgeries
• By end use, the hospitals segment held the largest market share in 2020 owing to the increasing number of hospitals
• Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising prevalence of chronic wounds

Medical Tapes And Bandages Market Segmentation

Grand View Research has segmented the global medical tapes and bandages market on the basis of product, application, end use, and region:

Medical Tapes & Bandages Product Outlook (Revenue, USD Million, 2016 - 2028)

• Medical Tapes
  • Fabric Tapes
    • Acetate
    • Viscose
    • Cotton
    • Silk
    • Polyester
    • Other Fabric Tapes
  • Paper Tapes
  • Plastic Tapes
    • Polypropylene
    • Other Plastic Tapes
  • Other Tapes
• Medical Bandages
  • Muslin Bandage Rolls
  • Elastic Bandage Rolls
  • Triangular Bandages
  • Orthopedic Bandages
  • Elastic Plaster Bandages
  • Other Bandages

Medical Tapes & Bandages Application Outlook (Revenue, USD Million, 2016 - 2028)

• Surgical Wound
• Traumatic Wound
• Ulcer
• Sports injury
• Burn injury
• Other injuries

Medical Tapes & Bandages End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals
• Ambulatory surgery centers
• Clinics
• Retail
• Others

Medical Tapes & Bandages Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
• Asia Pacific
  • Japan
  • China
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia

List of Key Players of Medical Tapes & Bandages Market

• Smith & Nephew PLC
• Mölnlycke Health Care AB
• Ethicon Inc. (JOHNSON & JOHNSON)
• Medtronic
• 3M
• Beiersdorf AG
• Urgo Medical
• Dynarex Corporation
• Winner Medical Group, Inc.
• McKesson Corporation
• Cardinal Health
• 3L Medicinal Products Group
• Braun Melsungen AG
• Paul Hartmann AG

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Preclinical CRO Market is Estimated To Expand at a CAGR of 8.1% through 2028

 

Preclinical CRO Market Growth & Trends

The global preclinical CRO market size is expected to reach USD 8.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The market is expected to witness lucrative growth over the forecast period due to increasing R&D expenditure and growing outsourcing trend. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market growth over the forecast period.

The market is undergoing a series of mergers and acquisitions, resulting in the improvement in full-service capabilities and international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations (CROs) are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs, and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.

The COVID-19 epidemic is ever increasing since it was first identified in China in December 2019. Until January 20, 2021, more than 96.7 million cases of COVID-19 were reported globally, with more than 2,068,303 deaths across the globe. This pandemic has fast-tracked the development of vaccine and drug testing. There are currently more than 50 COVID-19 vaccine candidates in preclinical studies as well as trials.

North America held the largest share of 47.7% in 2020. Significant investment in healthcare R&D, coupled with well-developed healthcare infrastructure in the U.S., is contributing to the largest share of North America. Asia Pacific is projected to expand at the fastest CAGR of 12.0% over the forecast period.

Request a free sample copy or view report summary: Preclinical CRO Market Report

Preclinical CRO Market Report Highlights

• By service, the toxicology testing segment accounted for the largest share of 61.1% in 2020 due to its significance in Investigational New Drug (IND)-enabling studies
• Based on end-use, the government and academic institutes segment is anticipated to register the highest CAGR of 8.4% over the forecast period due to improving government initiatives toward healthcare, especially in developing economies
• North America dominated the market in 2020 with a share of 47.7%. Significant healthcare expenditure on R&D is one of the major factors driving the market in this region

Preclinical CRO Market Segmentation

Grand View Research has segmented the global preclinical CRO market on the basis of service, end-use, and region:

Preclinical CRO Service Outlook (Revenue, USD Million, 2016 - 2028)

• Bioanalysis and DMPK Studies
• Toxicology Testing
• Others

Preclinical CRO End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Preclinical CRO Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Belgium
  • Switzerland
  • Russia
  • Sweden
• Asia Pacific
  • India
  • Japan
  • China
  • Australia
  • South Korea
  • Malaysia
  • Indonesia
  • Singapore
  • Philippines
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt

List of Key Players of Preclinical CRO Market

• Envigo Corporation
• MPI research
• Eurofins Scientific
• PRA Health Sciences, Inc.
• Wuxi AppTec
• Medpace, Inc.
• Pharmaceutical Product Development (PPD), LLC
• PARAXEL International Corporation
• ICON Plc
• Laboratory Corporation of America, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research    reports, customized research reports, and consulting services. To help clients make informed business    decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Pharmaceutical Robots Market is Expected to Grow High Due to Growing Need For Automation In Manufacturing Units by 2028

 

Pharmaceutical Robots Market Growth & Trends

The global pharmaceutical robots market size is expected to reach USD 297.4 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.3% from 2021 to 2028. The growing pharmaceutical industry and numerous benefits offered by robotic systems in product manufacturing, such as improved production output and product quality, increased production flexibility, lesser space utilization, no labor turnover, low operating costs, enhanced health and safety, reduced production downtime, and better waste management, are driving the adoption of these products, thereby aiding the market growth. According to an article published by Mint in April 2020, the adoption and usage of robotic technology are expected to increase in India across all types of healthcare settings, despite their high prices, owing to the availability of a smaller number of healthcare professionals for more than 1.3 billion population.

In 2020, the traditional robots product segment accounted for the largest revenue share owing to its increasing adoption in material handling, picking and packaging, palletizing, and inspection. Collaborative robots are anticipated to register the fastest growth rate during the forecast period. Many companies are replacing traditional with collaborative robots or cobots, which is a combination of humans and robotics. The adoption of cobots is significantly increasing as they combine repetitive tasks of robots and the individual skills of humans to bring in efficiency in manufacturing processes. These machines are also cheaper and easier to operate and maintain as compared to the traditional ones.

In 2020, the picking and packaging application segment accounted for the largest revenue share and is anticipated to witness the fastest growth during the forecast period. This growth can mainly be attributed to the high demand for personalized packaging and benefits associated with this segment, including high speed, efficient track and trace, and optimum utilization of the floor space. In addition, all the traditional robotic solutions are mainly used for picking and packaging. For instance, 6-axis articulated robots such as VP-6242G and VS-068A2 developed by Denso Wave Incorporated enable picking and packaging.

In 2020, the pharmaceutical companies end-use segment accounted for the largest revenue share and is anticipated to register the fastest growth rate during the forecast period. This is attributed to the increasing usage of robotics in drug discovery and development. In addition, pharmaceutical companies are involved in developing personalized medicine, which further supports the growth of the segment. Research laboratories are anticipated to witness significant growth during the forecast period owing to the ability of these automated solutions to perform repetitive tasks, such as moving test tubes and fluids, during drug discovery-related activities, facilitating a high rate of consistency and accuracy.

In 2020, Asia Pacific dominated the market and is anticipated to register the fastest growth rate during the forecast period. The rise in the demand for the production of drugs and the development of robotic machines for performing tasks with high speed, reduced risk of contamination, accuracy, and optimum utilization of space among pharmaceutical companies is boosting the regional market growth. Moreover, a rise in the number of initiatives undertaken by the government to increase the adoption of industrial robots is further aiding the regional market growth. For instance, in 2016, the Chinese government launched the Robotics Industry Development Plan (2016-2020), aimed at promoting robot applications to a wider range of fields and attracting foreign investment, to develop 100,000 industrial robots produced by domestic technology annually by 2020.

Request a free sample copy or view report summary: Pharmaceutical Robots Market Report

Pharmaceutical Robots Market Report Highlights

• The market growth is attributed to various technological advancements and increasing investments in the robotics sector
• In terms of product, traditional robots dominated the market in 2020 owing to the availability of different types of traditional products for specific applications
• Based on application, the picking and packaging segment dominated the market in 2020 owing to a rise in demand for personalized packaging
• By end use, pharmaceutical companies dominated the market in 2020 owing to the rapid rate of drug discovery and high investments by the companies
• Asia Pacific dominated the market in 2020 owing to the booming pharmaceutical and industrial robotics market in the region

Pharmaceutical Robots Market Segmentation

Grand View Research, Inc. has segmented the global pharmaceutical robots market on the basis of product, application, end-use, and region:

Pharmaceutical Robots Product Outlook (Revenue, USD Million, 2014 - 2028)

• Traditional Robots
  • Articulated Robots
  • SCARA Robots
  • Delta/Parallel Robots
  • Cartesian Robots
  • Dual-arm Robots
• Collaborative Pharmaceutical Robots

Pharmaceutical Robots Application Outlook (Revenue, USD Million, 2014 - 2028)

• Picking and Packaging 
• Inspection of Pharmaceutical Drugs 
• Laboratory Applications

Pharmaceutical Robots End-use Outlook (Revenue, USD Million, 2014 - 2028)

• Pharmaceutical Companies
• Research Laboratories

Pharmaceutical Robots Regional Outlook (Revenue, USD Million, 2014 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
• Asia Pacific
  • Japan
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa

List of Key Players of Pharmaceutical Robots Market

• ABB Ltd.
• Kawasaki Heavy Industries Ltd.
• Universal Robots A/S
• FANUC America Corporation
• Yaskawa Electric Corporation
• Marchesini Group S.p.A
• Seiko Epson Corporation
• Denso Wave, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Specialty Medical Chairs Market Is Expected To Gain Significant Traction Over The Forecast Period

 Specialty Medical Chairs Market Growth & Trends

The global specialty medical chairs market size is expected to reach USD 6.05 billion by 2028 registering a CAGR of 7.5%, according to a new report by Grand View Research, Inc. Increasing geriatric population is one of the major factors boosting the product adoption. As per the WHO, it is estimated that from 2025 to 2050, the older population is expected to almost double to 1.6 billion globally. According to The World Bank, the population in the Asia Pacific region is aging rapidly.

More than 211 million people aged 65 years and above were living in East Asia and Pacific in 2010. The older population is expected to grow by 22% every five years in East Asia. This shows the potential demand for geriatric chairs in the coming years. The rising prevalence of lifestyle-associated diseases, such as diabetes, obesity, chronic kidney disease, and Cardiovascular Diseases (CVDs), is also expected to augment the product demand. Furthermore, rising cases of paralysis and spinal injuries are anticipated to contribute to the market growth.

Increasing reimbursement policies and supportive regulatory frameworks in developed nations are also pushing the market growth. For instance, Medicare policies in the U.S. offer reimbursement for equipment, such as wheelchairs, recliners, and others. In addition, key market players are offering customized products to meet the various needs of doctors and patients. Rising demand for new, easy-to-use products with better facilities is expected to provide lucrative opportunities to the market participants.

The examination and treatment rate at dental, ophthalmic, and gynecology clinics has decreased significantly, which can be attributed to the lockdown imposed in various Asian countries due to the pandemic and growing preference for online consultations. Various domestic and international companies are facing major challenges in Japan and China due to the pandemic and the aftermath is expected to continue until the second half of 2021.

Moreover, the healthcare resources are currently directed toward essential medical devices and supplies. It is believed that the outbreak will lead to many changes, including preferences of the general public, leading to a decline in product demand. However, major countries in Asia, such as China and South Korea, are on a steady path to recovery. According to the Asian Development Bank, China’s growth is expected to rebound by about 7.3% by 2021.

Request a free sample copy or view report summary: Specialty Medical Chairs Market Report

Specialty Medical Chairs Market Report Highlights

• The rehabilitation product segment held the dominant share of over 40% in 2020 owing to rise in the geriatric population
• In 2020, dialysis chairs held the largest share in the examination product segment owing to the increased prevalence of chronic kidney diseases and rise in funding to centers for better equipment
• The treatment product segment is anticipated to register the fastest CAGR over the forecast period as these products are required for carrying out various treatment procedures, such as dental, and offer better comfort to patients during these procedures
• Asia Pacific is anticipated to be the fastest-growing regional market from 2021 to 2028 owing to improving healthcare infrastructure, growing geriatric population, and rising disposable income levels

Specialty Medical Chairs Market Segmentation

Grand View Research has segmented the global specialty medical chairs market on the basis of product and region:

Specialty Medical Chairs Product Outlook (Revenue, USD Million, 2016 - 2028)

• Examination
  • Birthing
  • Cardiac
  • Blood Drawing
  • Dialysis
  • Mammography
• Treatment
  • Ophthalmic
  • ENT
  • Dental
  • Others
• Rehabilitation
  • Pediatric
  • Bariatric
  • Geriatric
  • Others

Specialty Medical Chairs Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia

List of Key Players of Specialty Medical Chairs Market

• A-dec, Inc.
• ActiveAid, Inc.
• DentalEZ, Inc.
• Fresenius Medical Care AG & Co. KGaA
• Topcon Corp.
• Midmark Corp.
• Danaher (KaVo Dental GmbH)
• Dentsply Sirona
• Planmeca Oy
• Hill Laboratories Company

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Gene Expression Market to Reflect Steadfast Expansion During 2021-2028

 Gene Expression Market Growth & Trends

The global gene expression market size is anticipated to reach USD 19.4 billion by 2028 registering a CAGR of 9.96% from 2021 to 2028, according to a new report by Grand View Research, Inc. Rise in investments for the development of alternative drug discovery approaches coupled with an increase in research activities for genetic studies is expected to drive the global market.

A rise in awareness about the potential application of genetic studies has led to an increase in investments for the development and launch of novel products. For instance, in August 2020, Lexogen GmbH launched the QuantSeq-Pool Sample-Barcoded 3’ mRNA-Seq Library Prep Kit to expedite multiplexing capacities during gene expression profiling. The company’s new QuantSeq-Pool kit also facilitates the sequencing of up to 36,864 RNA samples in parallel, thereby reducing cost and time. 

Furthermore, the decrease in cost associated with sequencing posed as a major driver in the last few years. According to the National Human Genome Research Institute (NHGRI), the cost of sequencing per genome reduced from USD 46.77 thousand in 2010 to USD 0.689 thousand in 2020. This dramatic 98.5% decline in sequencing costs within a decade has increased research involving genomic expression profiling studies.

Request a free sample copy or view report summary: Gene Expression Market Report

Gene Expression Market Report Highlights

• cDNA synthesis & conversion dominated the process segment in 2020. High demand for personalized medicine coupled with technological advancements in sequencing techniques has enhanced the application of cDNA synthesis to produce genomic libraries
• Moreover, the introduction of systems that provide direct library synthesis has eliminated the need for prior steps, which increases revenue share
• Kits and reagents product generated the largest revenue in 2020 due to their high usage during the process
• In addition, ongoing innovation in the kits and reagents dedicated for specific applications contributes to the highest share of the segment
• High-Plex capacity is expected to register the fastest CAGR during the forecast period owing to the higher accuracy and increased application in cancer research
• RNA exp. was the largest revenue-contributing technique in 2020 owing to higher adoption of RNA exp. analysis
• Moreover, the introduction of high-throughput validation methods, such as targeted RNA sequencing, which are useful in broader screening technologies, has increased the revenue generation in the segment
• The drug discovery & development segment accounted for the largest revenue share in 2020 as Gene Exp. Signature (GES) is commonly used for the development of novel molecules for multifactorial cellular diseases like cancer, diabetes, tuberculosis, malaria, AIDS, and other infectious diseases
• North America was the dominant regional market in 2020. This can be attributed to the high adoption of advanced gene exp. technology in the region
• Major market participants, such as Thermo Fisher Scientific, Inc. and Agilent Technologies, have undertaken strategic initiatives to strengthen their position in the market
• In March 2020, Thermo Fisher Scientific, Inc. launched the PowerTrack SYBR Green PCR Master Mix for real-time PCR workflow. The product is intended to amplify targets for precise analysis

Gene Expression Market Segmentation

Grand View Research has segmented the global gene expression market on the basis of process, product, capacity, technique, application, and region:

Gene Expression Process Outlook (Revenue, USD Million, 2017 - 2028)

• Sample Collection
• Purification
• cDNA Synthesis & Conversion
• PCR Analysis
• Data Analysis & Interpretation

Gene Expression Product Outlook (Revenue, USD Million, 2017 - 2028)

• Kits & Reagents
• DNA Chip/Microarray
• Others

Gene Expression Capacity Outlook (Revenue, USD Million, 2017 - 2028)

• Low- to Mid-Plex
• High-Plex

Gene Expression Technique Outlook (Revenue, USD Million, 2017 - 2028)

• RNA Exp.
  • Northern Blotting
  • DNA Microarrays
  • PCR Techniques
  • RNA-Seq
• Promoter Analysis
  • In vitro Transcription/Nuclear Run-On Assays
  • Gel Shift Assays
  • Chromatin Immunoprecipitation (ChIP) Assays
• Protein Exp. & Posttranslational Modification Analysis
  • Western Blotting
  • 2-D Gel Electrophoresis
  • Immunoassays
  • Mass Spectrometry

Gene Expression Application Outlook (Revenue, USD Million, 2017 - 2028)

• Drug Discovery & Development
• Clinical Diagnostics
  • RNA Exp.
  • Other Techniques
• Biotechnology & Microbiology
• Others

Gene Expression Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • France
  • UK.
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East Africa (MEA)
  • South Africa
  • Saudi Arabia

List of Key Players of Gene Expression Market

• QIAGEN
• Quest Diagnostics, Inc.
• Hoffmann-La Roche Ltd.
• Illumina, Inc.
• PerkinElmer, Inc.
• Bio-Rad Laboratories
• Thermo Fisher Scientific, Inc.
• Agilent Technologies
• GE Healthcare
• Promega Corp.
• Luminex Corp.
• Takara Bio, Inc.
• Danaher Corp.
• ELITechGroup
• AutoGenomics
• Biocartis NV
• IntegraGen
• Interpace Biosciences, Inc.
• Fluidigm Corp.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

mHealth Apps Market Analysis, Industry Size, Share And New Opportunities Till 2028: Grand View Research Inc.

 

mHealth Apps Market Growth & Trends

The global mHealth apps market size is expected to reach USD 149.3 billion by 2028 and is expected to register a CAGR of 17.7% over the forecast period, according to a new report by Grand View Research, Inc. Growing promotion of mHealth applications due to their benefits in improving the lifestyle and treatment outcomes is one of the key factors driving the growth of this market. In addition, the use of mobile health applications can facilitate better patient experience and engagement.

North America was the dominant regional market in 2020 and accounted for a revenue share of 38.8%. Various factors like rapid growth in the usage of smartphones, developments in coverage networks, increasing prevalence of chronic diseases, and rise in geriatric population are driving the market growth in North America. In addition, rising demand for health and analytics solutions has led to increased adoption of such applications by healthcare providers and others. Increasing cases of chronic conditions requiring remote monitoring and treatment also boost the demand for mobile health platforms.

In addition, the Covid-19 pandemic has led to an increased utilization of mobile health platforms across the globe. Increasing remote patient monitoring and patient data analysis and diagnosis are major factors for the adoption of mobile health applications. For instance, data published by Statista providing a comparison between the number of mHealth or medical application downloads and the peak month of the pandemic signifies that there was around 135% increase in the medical application downloads in South Korea and around 65% rise at a global level. Hence, the pandemic has boosted product adoption, thereby fueling the market growth.

Request a free sample copy or view report summary: mHealth Apps Market Report

mHealth Apps Market Report Highlights

• The global market size is anticipated to be valued at USD 149.3 billion by 2028 owing to growing product adoption for better patient engagement and care
• Based on type, the market is broadly classified into medical and fitness apps. The medical applications segment dominated the market in 2020
• This is owing to high awareness levels about such applications and preference for their use by healthcare professionals, patients, and other consumers
• Medical applications are further classified into applications, such as women’s health, medication management, personal health record, diagnostic, remote monitoring, disease management, and others
• North America led the global market in 2020; however, Asia Pacific is projected to become the fastest-growing regional market over the forecast period

mHealth Apps Market Segmentation

Grand View Research has segmented the global mHealth apps market on the basis of type and region:

mHealth Apps Type Outlook (Revenue, USD Million, 2016 - 2028)

• Fitness Apps
  • Diet & Nutrition
  • Exercise & Fitness
  • Lifestyle & Stress
• Medical Apps
  • Women’s Health
  • Personal Health Record
  • Medication Management
  • Diagnostic
  • Remote Monitoring
  • Disease Management
  • Others

mHealth Apps Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of mHealth Apps Market

• Abbott Laboratories
• Johnson and Johnson
• AstraZeneca PLC
• Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Merck and Co., Inc.
• Pfizer, Inc.
• Sanofi
• Samsung Electronics Co. Ltd.
• Qualcomm Technologies, Inc.
• Orange
• Google (Alphabet), Inc.
• Allscripts
• Airstrip Technologies, Inc.
• AT&T
• Apple, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Central Nervous System Therapeutic Market Plying for Significant Growth During 2021-2028

 Central Nervous System Therapeutic Market Growth & Trends

The global central nervous system therapeutic market size is expected to reach USD 205.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2021 to 2028. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo’s zinc finger platform to develop therapies for Alzheimer’s disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Request a free sample copy or view report summary: Central Nervous System Therapeutic Market Report

Central Nervous System Therapeutic Market Report Highlights

• The neurodegenerative diseases segment accounted for the largest revenue share of nearly 40.0% in 2020 and is anticipated to maintain its dominance over the forecast period
• Pipeline candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are anticipated to drive the neurodegenerative disorder segment from 2021 to 2028
• The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
• In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
• North America held a majority of share in 2020 due to high awareness level in the region and better reimbursement scenario

Central Nervous System Therapeutic Market Segmentation

Grand View Research has segmented the global central nervous system therapeutic market on the basis of disease and region:

CNS Therapeutic Disease Outlook (Revenue, USD Million, 2017 - 2028)

• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others

CNS Therapeutic Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • India
  • China
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa

List of Key Players of Central Nervous System Therapeutic Market

• Biogen
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Merck & Co.
• Astra Zeneca
• Shire PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Pfizer, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Expansion of Ophthalmic Drugs Market During 2021– 2028 to Gain Robust Traction: Grand View Research Inc.

 Ophthalmic Drug Market Growth & Trends

The global ophthalmic drugs market size is expected to reach USD 60.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028. An increase in the prevalence of eye-related disorders, such as presbyopia, macular degeneration, and diabetic retinopathy, is one of the major drivers of the market. According to the American Academy of Ophthalmology, over 2.71 million people in the U.S. were affected by Primary Open-angle Glaucoma (POAG) in 2011, and the number is estimated to reach 7.3 million by 2050.

Moreover, due to COVID-19, it has become increasingly unsafe for individuals to touch their face several times a day, which is a known cause of transmission. Therefore, companies are developing long-acting, hands-free therapies to combat such challenges. For instance, in April 2020, Ocular Therapeutix, Inc. completed Phase III clinical trial to evaluate the safety and efficacy of DEXTENZA for allergic conjunctivitis. It is a hands-free therapy administered in the office setting as an intracanalicular insert. It is bioresorbable and designed to release the corticosteroid dexamethasone to the ocular surface, lasting 30 days. It is a one-time and long-acting therapy that can be useful during the COVID-19 crisis.

Investors are increasingly funding companies to support the clinical development of novel treatments for eye diseases thereby fueling the market growth. For instance, in February 2019, Oyster Point Pharma, Inc. received USD 93 million series B financing from Invus Opportunities, Flying L Partners, New Enterprise Associates (NEA), Versant Ventures, and Vida Ventures. The company’s product candidates include OC-01 and OC-02 in a Phase 2b clinical trial.

In addition, increasing development and approval of new laboratory methods is expected to boost the market growth. For instance, in July 2020, Quest Diagnostics received emergency Use Authorization (EUA) from the U.S. FDA for a laboratory technique that was developed for extracting viral RNA. This new technique was designed to expand the testing capacity of COVID-19 molecular tests.

Furthermore, key players in the market undertake various strategies to strengthen their product portfolios and offer diverse, technologically advanced, and innovative products. For instance, in September 2019, Alcon introduced iLUX Patient Care Kits to support practices in treating people with dry eyes in the U.S.

Request a free sample copy or view report summary: Ophthalmic Drug Market Report

Ophthalmic Drug Market Report Highlights

• In 2020, anti-VEGF agents dominated the market owing to high preference by ophthalmologists, enhanced tissue penetration, and rapid responsive rates
• Retinal disorders was the fastest-growing disease segment in 2020 owing to an increase in the prevalence of age-related macular degeneration and diabetic retinopathy, technological advancements, and rising strategic collaborations
• The topical route of administration dominated the market in 2020 due to the high patient compliance, non-invasiveness, and self-administrability
• The eye drops segment is estimated to witness the fastest growth over the forecast period due to impending launches of several ophthalmic solutions and suspensions in the near future and its direct drug delivery mechanism
• North America dominated the market and accounted for the largest revenue share in 2020 owing to the rising consumer awareness, high disease burden, technological advancements, and proactive government measures

Ophthalmic Drug Market Segmentation

Grand View Research has segmented the global ophthalmic drugs market on the basis of drug class, disease, dosage form, route of administration, product type, and region.

Ophthalmic Drugs Class Outlook (Revenue, USD Million, 2017 - 2028)

• Antiallergy
• Anti-VEGF Agents
• Anti-inflammatory
  • Nonsteroidal Drugs
  • Steroidal Drugs
• Antiglaucoma
• Others

Ophthalmic Drugs Disease Outlook (Revenue, USD Million, 2017 - 2028)

• Dry Eye
• Eye Allergy
• Glaucoma
• Eye Infection
• Retinal Disorders
  • Macular Degeneration
  • Diabetic Retinopathy
  • Others
• Uveitis
• Others

Ophthalmic Drugs Dosage Form Outlook (Revenue, USD Million, 2017 - 2028)

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Ophthalmic Drugs Route of Administration Outlook (Revenue, USD Million, 2017 - 2028)

• Topical
• Local Ocular
  • Subconjunctival
  • Intravitreal
  • Retrobulbar
  • Intracameral
• Systemic

Ophthalmic Drugs Product Type Outlook (Revenue, USD Million, 2017 - 2028)

• Prescription Drugs
• OTC Drugs

Ophthalmic Drugs Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • UAE
  • Saudi Arabia

List of Key Players of Ophthalmic Drugs Market

• Alcon
• Johnson & Johnson Services, Inc.
• Bausch Health
• Allergan
• Pfizer, Inc.
• Bayer AG
• Santen Pharmaceutical Co. Ltd.
• Genentech, Inc.
• Novartis AG
• Regeneron
• Merck & Co.
• Coherus Biosciences, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Biopharmaceutical CMO And CRO Market Growth Factors, Demand, Opportunities, Current Trends & Predictions

 Biopharmaceutical CMO & CRO Market Growth & Trends

The global biopharmaceutical CMO and CRO market size is expected to reach USD 49.2 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.6% from 2021 to 2028. The market is significantly driven by the growing interest of conventional drug developers in biological therapeutics. At present, outsourcing has become a cost-saving strategy for small to medium-sized bio-manufacturers as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel.

The global market for biopharmaceutical CMO and CRO is expected to thrive during the pandemic owing to positive pipeline development across modalities. For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future.

The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs and CROs to accelerate their business operations.

The mammalian source segment dominated the market in 2020. CMOs are engaged in standardizing their mammalian systems, thereby driving the revenue growth in the mammalian segment. Plant-based expression systems are developed and explored as a cost-effective alternative for the production of large molecules.

The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs.

However, these CMOs and CROs are facing competition from in-house departments of pharmaceutical and biotechnology companies. Several big pharma companies like Novartis announced to keep their biomanufacturing process in-house.

Some key CMOs are Lonza; Boehringer Ingelheim GmbH; Patheon; Samsung BioLogics; and FUJIFILM Diosynth Biotechnologies U.S.A., Inc. The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.

Request a free sample copy or view report summary: Biopharmaceutical CMO & CRO Market Report

Biopharmaceutical CMO & CRO Market Report Highlights

• Based on source, mammalian cell line-based bioproduction system accounted for the largest revenue share of 54.0% in 2020 due to the growth in mammalian system titers and yields
• By service type, contract manufacturing services accounted for the largest share of 57.7% in 2020 owing to the presence of a wide range of services from cell line development to the final packaging of the product
• Contract research services are expected to expand at the fastest CAGR of 8.4% over the forecast period. This can be attributed to increasing investment in research programs for the development of novel therapeutics
• In terms of product, biologics held the largest share of 81.8% in 2020. In recent times, biologics manufacturing is becoming more specialized, as a result of which CMOs have become an integral part of the biologics production strategies of clients
• North America held the largest share of 33.8% in 2020. The North American biopharmaceutical research industry is recognized as a leader in biopharmaceutical innovations. Several biopharma companies from the U.S. are considering Asian countries for the development of pharma products. This is primarily due to the growing costs of R&D in their home country and the presence of low-cost production facilities and cheap labor in Asian countries

Biopharmaceutical CMO & CRO Market Segmentation

Grand View Research has segmented the global biopharmaceutical CMO and CRO market on the basis of source, service type, product, and region:

Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2016 - 2028)

• Mammalian
• Non-mammalian

Biopharmaceutical CMO & CRO Service Type Outlook (Revenue, USD Million, 2016 - 2028)

• Contract Manufacturing
  • Process Development
    • Downstream
    • Upstream
  • Fill & Finish Operations
  • Analytical & QC studies
  • Packaging
• Contract Research
  • Oncology
  • Inflammation & Immunology
  • Cardiology
  • Neuroscience
  • Others

Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2016 - 2028)

• Biologics
  • Monoclonal antibodies (MABs)
  • Recombinant Proteins
  • Vaccines
  • Antisense, RNAi, & Molecular Therapy
  • Others
• Biosimilars

Biopharmaceutical CMO & CRO Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • France
• Asia Pacific
  • China
  • Japan
• Latin America
  • Brazil
• Middle East & Africa
  • South Africa

List of Key Players of the Biopharmaceutical CMO & CRO Market

• Boehringer Ingelheim GmbH
• Lonza
• Inno Biologics Sdn Bhd
• Rentschler Biotechnologie GmbH
• JRS PHARMA
• BIOMEVA GmbH
• ProBioGen
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• TOYOBO CO., LTD.
• Samsung BioLogics

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Bioanalytical Testing Services Market: Advanced Technologies and Growth Opportunities Worldwide By 2028

 Bioanalytical Testing Services Market Growth & Trends

The global bioanalytical testing services market size is anticipated to reach USD 6.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2021 to 2028. The economic efficiency offered for outsourcing as compared to conducting an in-house study is encouraging the outsourcing of these services that is expected to boost the demand over the forecast period. Innovation or new molecule development is directly proportional to the demand for testing services. Due to pricing concerns, competitive pressures, and lead-time to market, companies are opting for outsourcing of testing services. The growing focus on customized care as well as on technological advancements is lowering the molecule lifecycle, which has resulted into rapid development of new molecules.

The market player’s performance in the pharmaceutical analytical testing domain is greatly influenced by the demand from end-user. Due to the increasing awareness level, intense market efforts, government initiatives, and improving accessibility, consumers, these days, are more anxious about personal care, leading to higher consumption of pharmaceutical products. The consumption levels are projected to rise exponentially over the forecast period.

Due to Covid-19 many universities has imposed complete campus lockdown and various other bioanalytical laboratories were suspended for sometimes. This has adversely impacted bioanalytical testing services industry. Also ‘wet lab’ bioanalytical research came to a complete standstill at several universities. But based on recent circumstances the situation has improved for many bioanalytical testing laboratories where activities can be continued in modified forms based on new guidelines. 

Request a free sample copy or view report summary: Bioanalytical Testing Services Market Report

Bioanalytical Testing Services Market Report Highlights

• Small molecule bioanalytical testing services held a lucrative share in 2020. This can be attributed to the maximum generic and branded drug compounds coming under this category
• The Bioavailability (BA) segment dominated the market in 2020 owing to the great demand for these services in generic drug manufacturing. Moreover, with the emergence of biosimilars, the demand for BA studies is expected to increase over the forecast period
• North America dominated the market in 2020. This can be attributed to the fact that it is one of the top manufacturing hubs of highly reliable, complex, and high-end pharmaceuticals
• Asia Pacific region is anticipated to witness the fastest CAGR over the forecast period. This is owing to many developed countries investing in the Asia Pacific region and various amendments to change the clinical trials evaluation standards according to the global platform

Bioanalytical Testing Services Market Segmentation

Grand View Research has segmented the global bioanalytical testing services market based on molecule type, test type, workflow, and region:

Bioanalytical Testing Services Molecule Type Outlook (Revenue, USD Million, 2016 - 2028)

• Small Molecule
• Large Molecule
  • LC-MS Studies
  • Immunoassays
    • PK
    • ADA
    • Others
  • Others

Bioanalytical Testing Services Test Type Outlook (Revenue, USD Million, 2016 - 2028)

• ADME
  • In-Vivo
  • In-Vitro
• PK
• PD
• Bioavailability
• Bioequivalence
• Others

Bioanalytical Testing Services Workflow Outlook (Revenue, USD Million, 2016 - 2028)

• Sample Preparation
  • Protein Precipitation
  • Liquid-Liquid Extraction
  • Solid Phase Extraction
• Sample Analysis
  • Hyphenated technique
  • Chromatographic technique
  • Electrophoresis
  • Ligand Binding Assay
  • Mass Spectrometry
  • Nuclear Magnetic Resonance
• Other Processes

Bioanalytical Testing Services Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • India
  • China
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Bioanalytical Testing Services Market

• PPD
• ICON plc
• Covance Inc.
• LabCorp
• Charles River Laboratories International, Inc.
• inVentiv Health
• SGS SA
• Toxikon, Inc.
• Intertek group
• Pace Analytical Services, LLC

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Flow Cytometry Market is Poised to Exhibit A Moderate 8.9% CAGR through 2027: Grand View Research Inc.

 

Flow Cytometry Market Growth & Trends

The global flow cytometry market size is expected to reach a value of USD 11.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.9% from 2021 to 2027. The high prevalence of chronic diseases, the introduction of technologically advanced flow cytometry solutions, and increasing R&D investments in the pharmaceutical industry are expected to propel market growth over the forecast period.

Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. Also, in January 2019, Beckman Coulter, a subsidiary of Danaher Corporation, expanded its clinical flow cytometry portfolio with the launch of its new ClearLLab 10C System. This newly launched integrated solution provides a standardized workflow that offers reliability and consistent clinical findings.

Technological advancements, resulting in enhanced accuracy, portability, and cost-effectiveness, are expected to present this market with future growth opportunities. Small-sized high-throughput cytometers are anticipated to gain popularity in the near future due to their associated benefits, such as ease of use and cost-effectiveness. Furthermore, improvements in fluorescent dyes and the introduction of bench-top cytometers are factors expected to drive market growth. Rapid advancements in multicolor flow cytometry, which has extensive applications in new drug development, have led to an easy cellular analysis by simultaneous evaluation of several parameters. These devices are extensively adopted by many contract research organizations.

Furthermore, the increasing prevalence of cancer, immunodeficiency disorders, and infectious diseases, including the outbreak of COVID-19, has significantly driven the demand for flow cytometry solutions for research and clinical applications. As per the American Cancer Society estimates, in 2020, around 1.8 million new cancer cases will be diagnosed in the U.S. Also, according to the data published by the National Cancer Institute (NCI), as of January 2019, there were around 16.9 million cancer survivors in the U.S.

Request a free sample copy or view report summary: Flow Cytometry Market Report

Flow Cytometry Market Report Highlights

• Instruments accounted for the largest market share in 2020, owing to its high demand for commercial and clinical applications
• The software segment is expected to register the fastest growth owing to new product developments in this field
• The research segment is anticipated to witness lucrative CAGR over the forecast period owing to increasing R&D activities pertaining to cancer and infectious diseases
• The outbreak of COVID-19 has drastically upsurged the demand for advanced flow cytometry solutions for research purposes
• North America dominated the market and accounted for the largest revenue share in 2020. Well-established healthcare infrastructure and the presence of an established pharmaceutical industry are facilitating the dominance of this region during the study period
• The Asia Pacific region is expected to witness significant growth owing to the increasing demand for flow cytometry solutions in emerging economies such as China and India

Flow Cytometry Market Segmentation

Grand View Research has segmented the global flow cytometry market on the basis of product, technology, application, end-use, and region:

Flow Cytometry Product Outlook (Revenue, USD Million, 2016 - 2027)

• Instruments
  • Cell Analyzers
  • Cell Sorters
• Reagents & Consumables
• Software
• Accessories
• Services

Flow Cytometry Technology Outlook (Revenue, USD Million, 2016 - 2027)

• Cell-based
• Bead-based

Flow Cytometry Application Outlook (Revenue, USD Million, 2016 - 2027)

• Research
  • Pharmaceutical
    • Drug Discovery
    • Stem Cell
    • In Vitro Toxicity
  • Apoptosis
  • Cell Sorting
  • Cell Cycle Analysis
  • Immunology
  • Cell Viability
• Industrial
• Clinical
  • Cancer
  • Organ Transplantation
  • Immunodeficiency
  • Hematology

Flow Cytometry End-use Outlook (Revenue, USD Million, 2016 - 2027)

• Commercial Organizations
• Hospitals
• Academic Institutes
• Clinical Testing Labs

Flow Cytometry Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • Spain
  • France
  • Italy
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Flow Cytometry Market

• Danaher Corporation
• Becton, Dickinson and Company
• Luminex Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Miltenyi Biotec
• Sysmex Corporation
• Stratedigm, Inc.
• Apogee Flow Systems Ltd.
• Sony Biotechnology, Inc.
• Thermo Fisher Scientific, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research    reports, customized research reports, and consulting services. To help clients make informed business    decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Kidney Function Tests Market Is Expected To Reach $1.25 Billion By 2028

 

Kidney Function Tests Market Growth & Trends

The global kidney function tests market size is expected to reach USD 1.25 billion by 2028 registering a CAGR of 6.2% from 2021 to 2028, according to a new report by Grand View Research, Inc. The introduction of innovative products, increasing R&D investments, and growing prevalence of kidney diseases are expected to propel market growth over the forecast period. Key players operating in the market are involved in extensive R&D initiatives for the development and launch of novel products to strengthen their position in the market.

For instance, in August 2020, RenalytixAI, a U.K.-based in vitro diagnostics company, submitted a 510(k) application to the FDA for its new KidneyIntelX assay. It is an Artificial Intelligence (AI)-enabled clinical diagnostic test designed to diagnose and enhance the clinical management of Type II diabetes patients with fast-progressing kidney disease. The emergence of such technologically advanced products is expected to impel market growth during the study period.

According to the data published by the CDC, in 2019, an estimated 15% of adults in the U.S. had Chronic Kidney Disease (CKD). The same source also stated that diabetes and high blood pressure are the major causes of CKD in adults, and CKD is more common in people aged 65 years or older. However, the low diagnosis rate of CKD is anticipated to be a major factor hampering the market growth. As per the data published by the National Kidney Foundation, approximately 90% of people suffering from CKD are not aware of it, leading to a limited number of diagnoses.

Request a free sample copy or view report summary: Kidney Function Tests Market Report

Kidney Function Tests Market Report Highlights

• Clearance test emerged as the largest product segment as it is the gold standard for monitoring and measurement of glomerular filtration rate
• Increased risk of diabetes and blood pressure due to the unhealthy lifestyle, especially during Covid-19 lockdowns, may lead to the high prevalence of CKD. Thus, creating high product demand in the near future
• The hospitals end-use segment dominated the market in 2020 owing to the rising awareness about CKD and increasing hospital visits for its management
• Diagnostic laboratories is estimated to be the fastest-growing end-use segment from 2021 to 2028 as these laboratories offer cost-effective services and fast & accurate results
• North America led the market with the largest revenue share in 2020 due to well-established healthcare infrastructure, favorable reimbursement scenario, and the presence of major players in the region
• Asia Pacific is projected to witness the fastest CAGR during the forecast period owing to the increasing incidence of CKD in emerging countries, such as China and India

Kidney Function Tests Market Segmentation

Grand View Research has segmented the global kidney function tests market on the basis of product, end-use, and region:

Kidney Function Tests Product Outlook (Revenue, USD Million, 2016 - 2028)

• Clearance Tests
• Urine Tests
• Blood Tests
• Dilution and Concentration Tests
• Other Tests

Kidney Function Tests End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals
• Diagnostic Laboratories
• Research Laboratories and Institutes
• Others

Kidney Function Tests Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • Spain
  • France
  • Italy
  • Russia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Kidney Function Tests Market

• Abbott Laboratories
• Danaher Corporation (Beckman Coulter, Inc.)
• Hoffmann-La Roche
• Sysmex Corporation
• Siemens Healthineers
• Randox Laboratories
• Quest Diagnostics
• Acon Laboratories
• Nova Biomedical
• Laboratory Corporation of America Holdings (LabCorp)

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research    reports, customized research reports, and consulting services. To help clients make informed business    decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Fundus Cameras Market Size Is Predicted To Reach A Valuation Of USD 470.4 Million By 2028: Grand View Research Inc.

 Fundus Cameras Market Growth & Trends

The global fundus cameras market size is expected to reach USD 470.4 million by 2028, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.8% from 2021 to 2028. The rising geriatric population and growing occurrences of chronic disorders such as diabetes and hypertension further increase the incidence of retinal disorders.

For instance, according to the WHO 2016 report, globally, in 2014, 422.0 million people had diabetes. Additionally, increasing non-communicable diseases such as AMD, diabetic retinopathy, and glaucoma is contributing to the growing blind population globally. Therefore, to control the impact of these eye diseases, the fundus camera is widely used for diagnosis purposes. Availability of different types of fundus cameras such as hybrid, portable, handheld, and standalone is expected to propel the market growth during the forecast period.

Diabetic Retinopathy (DR), Retinopathy of Prematurity (ROP), and Age-Related Macular Degeneration (AMD) are major and increasing causes of retinal blindness. An increase in life expectancy has led to a rise in the geriatric population, which would further continue to rise in the future. According to the U.S. Census Bureau, international database, the global geriatric population was nearly 617.1 million in 2015 and is anticipated to reach 998.7 by 2030. This, in turn, is expected to drive the overall market growth during the forecast period.

In addition, supportive government regulations for fundus cameras are expected to fuel the market growth during the forecast period. For instance, regulatory agencies in the U.S. and Japan stated that the cameras should be replaced every 4 years. This initiative by the agencies will help in implementing new advancements in fundus photography every 4 years, thereby, enhancing the diagnosis of eye diseases. However, the presence of other advanced technologies such as OCT for the diagnosis of eye problems is expected to hinder the adoption of fundus cameras and may impact the overall market growth during the forecast period.

Request a free sample copy or view report summary: Fundus Cameras Market Report

Fundus Cameras Market Report Highlights

• The non-mydriatic fundus cameras segment dominated the market in 2020 due to increased demand, as it enables the practitioner to view the retinal anatomy in detail and provides enhanced diagnosis and management of eye diseases
• Non-mydriatic and mydriatic camera can be further sub-segmented into tabletop and handheld. The tabletop segment dominated the market in 2020 because of the availability of a higher number of commercialized products and the ability to produce a better image quality than handheld products
• By end use, the ophthalmic and optometrist offices segment is expected to grow at the fastest rate during the forecast period due to the availability of well-equipped offices in North America and Europe, and the preference of patients for primary eye care
• North America dominated the market in 2020 and is expected to maintain its position during the forecast period, due to the local presence of major players and increased awareness about eye disorders
• In Asia Pacific, the market is anticipated to be the fastest-growing segment during the forecast period due to rising healthcare expenditure and increasing cases of retinal detachment, DR, and AMD

Fundus Cameras Market Segmentation

Grand View Research has segmented the global fundus cameras market based on product, end-use, and region:

Fundus Cameras Product Outlook (Revenue, USD Million, 2016 - 2028)

• Mydriatic Fundus Cameras
  • Tabletop
  • Handheld
• Non-Mydriatic Fundus Cameras
  • Tabletop
  • Handheld
• Hybrid Fundus Cameras
• ROP Fundus Cameras

Fundus Cameras End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals
• Ophthalmology Clinics
• Ophthalmic & Optometrist Offices

Fundus Cameras Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • The Netherlands
  • Russia
  • Switzerland
  • Poland
  • Turkey
• Asia Pacific
  • China
  • Japan
  • India
  • Thailand
  • South Korea
  • Indonesia
  • Taiwan
  • Hong Kong
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar

List of Key Players of Fundus Cameras Market

• Carl Zeiss Meditec, Inc.
• Kowa Company Ltd.
• Optomed Oy (Ltd.)
• Optovue, Incorporated
• CenterVue SpA
• NIDEK Co., Ltd.
• Topcon Medical Systems, Inc.
• Clarity Medical Systems, Inc.
• Canon, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Non-invasive Prenatal Testing Market Outlook, Leading Manufacturers, Industry Analysis And Forecast

 Non-invasive Prenatal Testing Market Growth & Trends

The global non invasive prenatal testing market size is anticipated to reach USD 6.5 billion by 2028 registering a CAGR of 10.9%, according to a new report by Grand View Research, Inc. High adoption and demand for early non-invasive prenatal testing (NIPT) coupled with improvements in reimbursement scenario are among the factors driving the market.

The use of invasive techniques of prenatal testing, such as chorionic villus sampling and amniocentesis, can lead to issues, such as miscarriage. This has led to a decline in the use of these procedures and high demand for tests that are more efficient, non-invasive, and safe. Furthermore, non-invasive fetal tests have a lower failure and false-positive rate, which has resulted in a considerable increase in uptake of non-invasive tests in the last few years.

The non-invasive prenatal testing market is highly saturated with the existing key players. Companies are forming partnerships and collaborations to maintain a stable position in the market. For instance, in August 2020, Eurofins Scientific announced an agreement with Noritsu Koki Co., Ltd. for the acquisition of GeneTech Inc., one of the pioneering NIPT developers in Japan. With this acquisition, Eurofins Scientific is set to strengthen its presence in the Japanese NIPT market.

Request a free sample copy or view report summary: Non-invasive Prenatal Testing Market Report

Non-invasive Prenatal Testing Market Report Highlights

• The 13-24 weeks gestation period segment accounted for the largest revenue share in 2020 owing to the presence of a maximum number of tests carried out in this phase of pregnancy
• NIPT for high- & average-risk pregnancy led the market owing to the presence of favorable payer reimbursement policies in this segment
• Next-Generation Sequencing(NGS) is estimated to be the largest as well as the fastest-growing technology segment from 2021 to 2028, as NGS is the most commonly used method for NIPT
• The diagnostic laboratories end-use segment held the largest revenue share in 2020 and will expand further at the fastest CAGR from 2021 to 2028 due to the rising number of diagnostic laboratories across the globe that offer NIPT
• Asia Pacific is expected to register the fastest year-on-year growth owing to the gradually increasing average maternal age and rising incidence of chromosomal aneuploidies
• One of the key trends followed by market participants includes licensing of the test to other labs and generating significant revenue by collecting royalty payments

Non-invasive Prenatal Testing Market Segmentation

Grand View Research has segmented the global non-invasive prenatal testing market on the basis of the gestation period, risk type, method, technology, product, end-use, and region:

NIPT Gestation Period Outlook (Revenue, USD Million, 2017 - 2028)

• 0-12 Weeks
• 13-24 Weeks
• 25-36 Weeks

NIPT Risk Type Outlook (Revenue, USD Million, 2017 - 2028)

• High & Average Risk
• Low Risk

NIPT Method Outlook (Revenue, USD Million, 2017 - 2028)

• Ultrasound Detection
• Biochemical Screening Tests
• Cell-Free DNA in Maternal Plasma Tests

NIPT Technology Outlook (Revenue, USD Million, 2017 - 2028)

• NGS
• Array Technology
• PCR
• Other Technologies

NIPT Product Outlook (Revenue, USD Million, 2017 - 2028)

• Consumables & Reagents
• Instruments

NIPT End-use Outlook (Revenue, USD Million, 2017 - 2028)

• Hospitals & Clinics
• Diagnostic Laboratories

NIPT Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Singapore
  • Australia
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia

List of Key Players of Non-invasive Prenatal Testing Market

• Genesis Genetics (CooperSurgical, Inc.)
• Natera, Inc.
• Centogene N.V.
• Illumina, Inc. (Verinata Health, Inc.)
• Eurofins LifeCodexx GmbH
• MedGenome Labs Ltd.
• Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
• Myriad Women’s Health, Inc. (Myriad Genetics Inc/Counsyl, Inc.)
• Progenity, Inc.
• Qiagen
• Laboratory Corp. of America Holdings
• Quest Diagnostics, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.